Boehringer Ingelheim announces broad agreement with the U.S. Government to lower the cost of medicines for American patients and expand its U.S. footprint

Boehringer Ingelheim to expand R&D and pharmaceutical manufacturing, ensuring the bulk of its medicines for U.S. patients will be produced in the U.S. RIDGEFIELD, Conn., Dec. 19, 2025 /PRNewswire/ -- Boehringer Ingelheim, a 140-year-old family-owned biopharmaceutical company committed to...